Your browser is no longer supported. Please, upgrade your browser.
Settings
MRSN Mersana Therapeutics, Inc. daily Stock Chart
MRSN [NASD]
Mersana Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own0.80% Shs Outstand68.42M Perf Week9.50%
Market Cap1.71B Forward P/E- EPS next Y-1.34 Insider Trans-11.92% Shs Float66.92M Perf Month32.96%
Income-75.40M PEG- EPS next Q-0.32 Inst Own- Short Float9.76% Perf Quarter40.07%
Sales0.90M P/S1904.08 EPS this Y76.80% Inst Trans4.72% Short Ratio6.62 Perf Half Y9.94%
Book/sh3.70 P/B6.73 EPS next Y-0.80% ROA-37.50% Target Price27.40 Perf Year613.18%
Cash/sh3.93 P/C6.33 EPS next 5Y- ROE-45.20% 52W Range3.32 - 26.64 Perf YTD334.38%
Dividend- P/FCF- EPS past 5Y- ROI-36.10% 52W High-7.28% Beta2.46
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin- 52W Low643.95% ATR1.48
Employees83 Current Ratio13.00 Sales Q/Q-98.70% Oper. Margin- RSI (14)64.24 Volatility5.51% 7.52%
OptionableYes Debt/Eq0.02 EPS Q/Q6.40% Profit Margin- Rel Volume0.77 Prev Close24.89
ShortableYes LT Debt/Eq0.02 EarningsNov 09 BMO Payout- Avg Volume987.15K Price24.70
Recom1.50 SMA2011.09% SMA5021.36% SMA20054.09% Volume80,403 Change-0.76%
Sep-29-20Resumed JP Morgan Neutral $20
Apr-29-20Initiated BTIG Research Buy $14
Jan-21-20Reiterated H.C. Wainwright Buy $7 → $12
Mar-11-19Downgrade JP Morgan Neutral → Underweight
Nov-14-18Upgrade Leerink Partners Mkt Perform → Outperform
May-08-18Initiated Robert W. Baird Outperform
Mar-19-18Downgrade JP Morgan Overweight → Neutral
Nov-25-20 07:30AM  
Nov-24-20 04:01PM  
Nov-19-20 07:00PM  
Nov-18-20 04:02PM  
Nov-12-20 07:38AM  
Nov-11-20 09:00AM  
Nov-10-20 06:37AM  
Nov-09-20 07:30AM  
07:30AM  
06:15AM  
06:00AM  
Nov-05-20 10:51AM  
Nov-04-20 08:00AM  
Nov-02-20 08:00AM  
07:30AM  
Oct-14-20 05:05PM  
Oct-07-20 07:00AM  
Sep-29-20 12:23PM  
Sep-21-20 12:41PM  
Sep-17-20 06:00AM  
Sep-15-20 03:41PM  
11:48AM  
Sep-10-20 08:00AM  
Sep-09-20 07:30AM  
Sep-03-20 08:00AM  
Sep-02-20 04:05PM  
Aug-31-20 08:00AM  
Aug-26-20 02:00PM  
Aug-17-20 07:30AM  
Aug-11-20 12:25PM  
08:00AM  
Aug-10-20 07:30AM  
Aug-07-20 07:17AM  
06:00AM  
Aug-06-20 04:13PM  
Aug-04-20 12:19PM  
08:00AM  
07:30AM  
Jul-31-20 08:00AM  
Jul-09-20 05:40AM  
Jul-08-20 04:15PM  
Jul-01-20 09:40AM  
Jun-30-20 06:56AM  
Jun-26-20 07:50AM  
Jun-24-20 12:27PM  
Jun-22-20 09:05AM  
Jun-08-20 01:25PM  
Jun-04-20 08:30AM  
08:00AM  
Jun-02-20 05:24PM  
10:22AM  
Jun-01-20 08:34AM  
May-29-20 10:29AM  
May-28-20 11:25PM  
05:00PM  
10:04AM  
09:42AM  
08:55AM  
06:00AM  
May-27-20 06:33PM  
11:39AM  
11:20AM  
06:00AM  
May-20-20 07:28AM  
May-15-20 08:00AM  
07:00AM  
May-14-20 04:05PM  
May-13-20 05:00PM  
09:49AM  
08:00AM  
May-12-20 08:04AM  
May-11-20 06:52AM  
May-09-20 11:30PM  
May-08-20 07:56AM  
06:00AM  
May-04-20 12:24PM  
Apr-29-20 04:05PM  
Apr-24-20 08:30PM  
08:47AM  
Apr-20-20 09:06AM  
07:52AM  
Apr-15-20 08:00AM  
Apr-14-20 09:13AM  
Apr-10-20 01:49PM  
Apr-08-20 07:53AM  
Apr-07-20 10:07PM  
Mar-30-20 04:01PM  
Mar-20-20 08:00AM  
Mar-03-20 07:07AM  
Feb-28-20 06:00AM  
Feb-21-20 08:00AM  
Feb-18-20 08:00AM  
Jan-21-20 08:57AM  
Jan-10-20 08:00AM  
Jan-02-20 08:00AM  
Dec-13-19 01:54PM  
Dec-06-19 09:47AM  
Nov-08-19 08:00AM  
Nov-06-19 06:00AM  
Oct-30-19 08:00AM  
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lowinger Timothy BChief Science & Tech. OfficerNov 20Option Exercise4.958,20340,5962,227Nov 24 04:31 PM
Lowinger Timothy BChief Science & Tech. OfficerNov 20Sale23.058,203189,0790Nov 24 04:31 PM
Lowinger Timothy BChief Science & Tech. OfficerOct 21Option Exercise4.954,10120,29619,078Oct 22 04:31 PM
Lowinger Timothy BChief Science & Tech. OfficerOct 21Sale17.504,10171,76816,851Oct 22 04:31 PM
Lowinger Timothy BChief Science & Tech. OfficerOct 20Option Exercise2.5620,95353,60516,851Oct 22 04:31 PM
Lowinger Timothy BChief Science & Tech. OfficerOct 20Sale16.744,10268,6670Oct 22 04:31 PM
Lowinger Timothy BChief Science, Tech. OfficerSep 21Option Exercise4.958,20340,59616,865Sep 23 04:30 PM
Lowinger Timothy BChief Science, Tech. OfficerSep 21Sale20.6620,614425,8320Sep 23 04:30 PM
Jack Eva M.Chief Bus. Officer, Tres, Sec.Sep 14Option Exercise1.5335,24853,92935,248Sep 16 06:31 PM
Jack Eva M.Chief Bus. Officer, Tres, Sec.Sep 14Sale22.0035,248775,4560Sep 16 06:31 PM
Mandelia AshishVP, ControllerJul 02Sale22.493,38376,0840Jul 06 04:15 PM
Alleva Lawrence MDirectorJun 01Buy22.951,08524,9011,085Jun 03 05:30 PM
SANDELL SCOTT D10% OwnerApr 14Sale9.225485,0530Apr 14 05:54 PM
SANDELL SCOTT D10% OwnerApr 13Sale8.981,65014,8120Apr 14 05:54 PM
BASKETT FOREST10% OwnerApr 13Sale8.583,19027,3580Apr 14 05:54 PM
SANDELL SCOTT D10% OwnerApr 13Sale8.5020,914177,7750Apr 13 09:10 PM
BASKETT FOREST10% OwnerApr 13Sale8.5020,914177,7750Apr 13 09:06 PM
Florence Anthony A. Jr.10% OwnerApr 13Sale8.5020,914177,7750Apr 13 09:06 PM
Hack Andrew A. F.DirectorApr 07Buy5.993,445,66720,649,4633,445,667Apr 09 04:11 PM
MOTT DAVID MDirectorApr 07Buy5.59538,5993,010,768538,599Apr 09 03:31 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.